Clinical Trials Browser

Completed × Lymphoma, T-Cell, Peripheral × 90 days × Clear all

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT04569032 2026-02-18

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Phase 2 Completed

82 enrolled 13 charts

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT02362997 2026-02-12

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Phase 2 Completed

82 enrolled 20 charts

Lymphoid

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Phase 1 Completed

26 enrolled 24 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02264613 2026-01-13

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

Phase 1/2 Completed

142 enrolled 30 charts

Lymphoid

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT06511895 2025-12-24

AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)

Phase 2 Completed

57 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

Clinical Trials

RELATIVITY-069

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)